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Abstract
Background: To analyze differences in the recognition of anti-citrullinated peptide/protein antibody (ACPA)
citrullinated epitopes and isotypes in patients with palindromic rheumatism (PR) and rheumatoid arthritis (RA).
Methods: ACPA fine specificities (citrullinated peptides of enolase, fibrin, and vimentin) and isotypes (IgG, IgM, and IgA)
were analyzed in 54 patients with longstanding PR and 54 patients with established RA.
Results: CCP2 tested positive in 66.7% of patients with PR and RA. The ACPA distribution of fine specificities and
isotypes differed between PR and RA patients. PR patients had a lower frequency of fine ACPA specificities than RA
patients, which was significant in the case of a peptide derived from vimentin (PR 24.1% vs. 59.3% RA; p < 0.001). The
mean number of ACPA specificities was lower in PR than in RA patients, and only 25.9% of PR patients recognized ≥2
additional specificities compared with 46.3% of RA patients. Significantly less isotype usage, especially IgA, was
observed in PR patients.
Conclusion: The ACPA immune response differed in patients with PR and RA, with fewer fine specificities and isotype
usage in patients with PR. Some patients with PR may have impaired maturation of the B-cell response against
citrullinated peptides with no progression to RA.
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Background
Palindromic rheumatism (PR), an intermittent form of
arthritis, may, in some cases, evolve to rheumatoid arth-
ritis (RA) [1]. A considerable proportion of PR patients
have the characteristic autoantibodies found in RA:
rheumatoid factor (RF) and/or anti-citrullinated peptide/
protein antibodies (ACPA). Our first description of the
high frequency of ACPA in the sera of PR patients [2] has
been confirmed by subsequent studies [3–5]. The ACPA
reactivities observed in serum of patients with PR are
citrulline-dependent as occurs in RA [6]. ACPA positivity
in the early phases of PR has been associated with a high
risk of evolution to RA [3]. However, a significant propor-
tion of patients with PR do not evolve to RA in the long-
term, even when ACPA are positive [7]. It remains unclear
whether PR is a separate disease entity, an incomplete ex-
pression of RA, or a preclinical stage of RA [8].
ACPA may precede the onset of clinical RA by several
years. Studies show that ACPA may be directed against
several citrullinated peptides, with epitope spreading oc-
curring over several years prior to RA onset [9]. ACPA
fine specificities remain relatively stable after the defini-
tive clinical diagnosis of RA [10]. The isotype usage of
ACPA may differ in the disease phases, with less isotype
usage in the preclinical stage [11, 12].
We hypothesized that ACPA responses may differ be-
tween patients with PR and RA. The ACPA immune re-
sponse in PR would be closer to that observed in healthy
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subjects or in the preclinical phase of RA, and this might
explain the absence of progression to RA in some PR pa-
tients. This study analyzed the differences in ACPA fine
specificities and isotype usage in patients with long-
standing PR who did not evolve to RA and in patients
with established RA.
Methods
Study populations
This cross-sectional study included patients diagnosed
with PR according to the criteria of Guerne and Weisman
[1] attending our Arthritis Unit from June 2012 to June
2013, with no evolution to RA or other rheumatic diseases
at the time of clinical and laboratory assessments; other
causes of intermittent arthritis were excluded. As controls,
we included patients with established RA (1987 ACR cri-
teria) controlled by gender, age (±5 years), disease dur-
ation (±3 years), and CCP2 positivity. Written consent
was obtained from all participants and the study was ap-
proved by the Hospital Clinic Ethics Committee.
CCP2 assay and measurement of ACPA fine specificities
and isotypes
IgG antiCCP2 was measured in serum samples by a
second-generation enzyme-linked immunosorbent assay
(ELISA; Immunoscan, Eurodiagnostica,; NV <50 UI).
The citrullinated peptides used in this study, whose pri-
mary sequences are detailed below, are derived from the
main protein targets of RA-specific autoantibodies: fibrin
[13], vimentin [14], and alpha-enolase [15].
ACPA fine specificities were determined by home-made
ELISA tests using synthetic citrullinated peptides previ-
ously studied by our group [16, 17] as antigens: fibrin
([Cit630]α-Fibrin(617-631)), vimentin ([Cit71]Vim(47-72)
and [Cit64,69,71]Vim(47-72)), and α-enolase [Cys4,22,
Cit9,15]α-Enolase(5-21); namely p18, p48, p55 and CEP-1,
respectively. Uncitrullinated peptides were also synthesized
and used as a control for citrulline specificity of the anti-
citrulline peptide antibodies in both RA and PR patients.
The ACPA isotypes IgG, IgA, and IgM of fine specificities
were measured using the corresponding secondary anti-
bodies (Jackson Immunoresearch) according to the previ-
ously described ELISA procedure [16, 17]. Cut-off values
for each ELISA test were determined using receiver operat-
ing characteristic (ROC) curves, with a specificity of 98%
compared with a healthy population (blood donors, n = 64).
Peptide synthesis
Citrullinated peptides [Cit630]α-fibrin(617-631): HSTK
RGHAKSRPVCitG (p18), [Cit71]Vim(47-72): STSRSL
YASSPGGVYATRSSAVRLCitS (p48), [Cit64,69,71]Vim
(47-72): STSRSLYASSPGGVYATCitSSAVCitLCitS (p55),
and [Cys4,22,Cit9,15]Enolase(5-21): CKIHACitEIFDSCitG
NPTVEC (CEP-1), and uncitrullinated versions α-
fibrin(617-631): HSTKRGHAKSRPVRG, Vim(47-72): ST
SRSLYASSPGGVYATRSSAVRLRS, and Enolase(5-21): C
KIHAREIFDSRGNPTVEC were synthesized by solid-
phase peptide synthesis as C-terminal carboxamides on
a Novasyn TGR resin (Novabiochem Merck, Germany)
(0.22 meq/g) and following a 9-fluorenylmethoxycarbonyl
(Fmoc) strategy. Couplings were performed by 2-(1H-7-
azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexa-
fluorophosphate (HATU) and diisopropylethylamine
(DIEA) activation, with three-fold molar excesses of
amino acids. The Fmoc deprotection step was performed
twice with 20% piperidine in dimethylformamide (DMF)
for 10 min. The peptides were concomitantly side chain-
deprotected and cleaved from the resin by treatment with
a mixture of TFA in the presence of triisopropylsilane
(TIS) and water as scavengers (TFA:TIS:H2O, 9.5:2.5:2.5)
for 3 h with occasional agitation at room temperature.
The solvent was removed in vacuum and the crude pep-
tides were precipitated with diethyl ether. The solids were
dissolved in 30% acetic acid in water and lyophilized.
Crude peptides were purified by semipreparative HPLC
(1260 Infinity, Agilent Technologies) in an XBridge™ Prep
BEH130 C18 column (Waters, 5 μm, 10 × 250 mm) at a
flow rate of 3.5 mL/min. Final peptides were characterized
by analytical HPLC on a 1260 Infinity chromatograph
(Agilent Technologies) with an Eclipse Plus C18 column
(Agilent, 3.5 μm, 4.6 × 100 mm). The peptides were 95%
pure by analytical HPLC at 220 nm. Their identity was
confirmed by electrospray ionization mass spectrometry
(ESI-MS) performed with a liquid chromatograph–time of
flight (LC-TOF) detector, LCT Premier XE (Micromass
Waters) coupled to Analytical Ultra Performance Liquid
Chromatography apparatus (UPLC, Waters).
For cyclization of CEP-1, its linear version was dis-
solved in 0.1 M ammonium bicarbonate (0.3 mg/mL).
The solution was left to stand open to the atmosphere
and stirred for 24 h. The formation of cyclic disulfide
was checked by the Ellman test.
ELISA assays
Peptide sequences were coupled covalently to ELISA mi-
croplates (Costar Corp., DNA-bind N-oxysuccinimide
surface, Cambridge, MA, USA). Peptides were diluted to
10 μg/mL in 0.05 M carbonate/bicarbonate (pH 9.6) buf-
fer; 100 μL of peptide solution was added to each well of
microplates and incubated overnight at 4 °C. Each plate
contained control wells that included all reagents except
the serum sample in order to estimate the background
reading and control wells that included all reagents ex-
cept the peptide to evaluate nonspecific reactions of
sera. For blank controls, wells were coupled with 2 μg
bovine serum albuin (BSA)/well. After incubation, the
plates were blocked with 2% BSA in 0.05 M carbonate/
bicarbonate (pH 9.6) buffer for 1 h at room temperature.
Cabrera-Villalba et al. Arthritis Research & Therapy  (2017) 19:141 Page 2 of 7
Sera were diluted 50-fold in RIA buffer (1% BSA, 350 mM
NaCl, 10 mM Tris-HCl, pH 7.6, 1% vol/vol Triton X-100,
0.5% wt/vol Na-deoxycholate, 0.1% SDS) supplemented
with 10% fetal bovine serum; 100 μL/well were added and
incubated for 1.5 h at room temperature. After washing six
times with phosphate-buffered saline (PBS)/0.05% Tween-
20, 100 μL/well of the anti-human secondary antibodies
conjugated to peroxidase at different dilutions in RIA buffer
(IgG 1:1000, IgA 1:2000, and IgM 1:40,000) were added.
After incubation for 1 h at room temperature, the plates
were washed six times with PBS/0.05% Tween-20 and
bound antibodies were detected with o-phenylenediamine
dihydrochloride (OPD; Sigma Chemical Company) and
0.8 μL/mL 30% hydrogen peroxide. The plates were incu-
bated at room temperature for 30 min. The reaction was
stopped with 50 μL of 2 N H2SO4 per well and absorbance
values were measured at a wavelength of 492 nm.
All sera were tested in duplicate. Control sera were also
included to monitor inter- and intra-assay variations.
Cut-off values and specificity control
ROC curve analysis and regression analysis were con-
ducted using the GraphPad Prism4 program and cut-off
values for each test were determined with a specificity of
98% compared with a healthy population of blood donors
(n = 64). Positive values were defined as follows: >0.188
optical density (OD) units for IgG anti-p18, >0.268 OD
units for IgA anti-p18, >0.302 OD units for IgM anti-p18,
>0.352 OD units for IgG anti-p48, >0.214 OD units for
IgG anti-p55, >0.384 OD units for IgA anti-p55, >0.234
OD units for IgM anti-p55, >0.226 OD units for IgG anti-
CEP-1, >0.810 OD units for IgA anti-CEP-1, and >0.358
OD units for IgM anti-CEP-1. RF was determined by
nephelometry (NV <20 UI).
Microtiter plates coated with uncitrullinated peptides
were used as a control for citrulline specificity of the
anti-citrulline peptide antibodies. The OD values on the
arginine variants were clearly bellow the citrulline respect-
ive peptide cut-off values. The number of patients who
recognized both the citrullinated and the arginine-
containing peptide with similar OD values, and thus are
considered not to bind to the respective peptide in a
citrulline-specific way, was very small. In this sense, only
one serum of RA (4.7% of the 21 IgG anti-CEP-1-positive)
and another one RA serum (3.6% of the 28 IgA anti-p18-
positive sera) reacted against the respective arginine con-
trol peptides of p18 and CEP-1. Besides, for the PR sera
included in this study, only one serum (5.9% of the 17 IgG
anti-CEP-1-positive sera) reacted against the uncitrulli-
nated CEP-1 peptide. These three patients were consid-
ered negative for the presence of IgG and IgA anti-CEP-1
and anti-p18 antibodies because no specific response was
detectable.
Statistical analysis
Continuous data are presented as means and standard de-
viation and categorical variables as absolute frequencies
and percentages. Differences in demographic, clinical, and
ACPA fine specificities and isotypes were compared be-
tween PR and RA patients. For continuous variables, we
used the Student’s or Mann-Whitney tests. For binary var-
iables, we used the Chi-square or Fisher’s exact tests,
when appropriate. Differences in reactivity of OD values
between PR and RA patients were analyzed using the
Mann-Whitney test. We analyzed anti-CCP2 reactivity
levels according to the number of IgG specificities using
Spearman’s correlation test. The level of statistical signifi-
cance was established as ≤0.05. The analysis was made
using R version 3.2.0 (copyright ©2015, The R Foundation
for Statistical Computing).
Results
Patient characteristics
We included 54 PR patients and 54 RA patients (62.9% fe-
male, 66.7% CCP2-positive in both groups). There were
no significant between-group differences in mean age, dis-
ease duration, and RF positivity (Table 1). The demo-
graphic and clinical characteristics of patients with PR are
described elsewhere [18].
IgG ACPA fine specificities
PR patients had a lower frequency of some IgG ACPA
fine specificities than RA patients, which was significant
for the two vimentin-derived peptides, p48 vimentin
(1.9% RP vs. 14.8% AR, p = 0.03) and, especially, p55
vimentin (PR 24.1% vs. 59.3% RA; p < 0.001) (Table 2).
The mean number of additional ACPA specificities
(p48 and p55 were grouped into one) was lower in PR pa-
tients (0.91 ± 0.96 vs. 1.43 ± 1.03; p = 0.008). Only 25.9% of
PR patients recognized ≥2 additional IgG ACPA specific-
ities compared with 46.3% of RA patients (p = 0.028)
(Table 3).
Table 1 Clinical and serological characteristics of patients with
palindromic rheumatism (PR) and rheumatoid arthritis (RA)
PR (n = 54) RA (n = 54) p
Female, n (%) 34 (62.9) 34 (62.9) NS
Age (year), mean ± SD 51.2 ± 11.3 54.7 ± 11.8 NS
Disease duration (years),
mean ± SD
11.6 ± 10.7 8.3 ± 6.1 NS
RF n (%) 31 (57.4) 30 (55.6) NS
RF levelsa, mean ± SD 237.3 ± 300.6 379.6 ± 715.9 NS
CCP2 n (%) 36 (66.7) 36 (66.7) NS
CCP2 levelsa, mean ± SD 392.6 ± 527.6 487.4 ± 584.4 NS
aMeasured only in positive patients
CCP cyclic citrullinated peptide, NS not significant, RA rheumatoid arthritis, RF
Rheumatoid factor
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Significantly higher levels of IgG ACPA fine specific-
ities were found in RA patients compared with PR pa-
tients, except for the enolase peptide, when all samples
were considered; however, no significant differences
were found when negative samples were excluded except
for IgG enolase, which was higher in PR (Fig. 1a, b, c,
and d). Comparison of the 18 CCP2-negative patients in
each group showed that p48/p55 vimentin was lower in
PR patients (5.6% vs. 38.9%; p = 0.04) and that PR pa-
tients had a lower mean number of positive specificities
(0.17 ± 0.5 PR vs. 0.56 ± 0.6 RA; p = 0.04).
CCP2 antibody levels correlated with the number of
citrullinated epitopes recognized by ACPA in RA, but to
a lesser extent in PR (Fig. 2).
IgA and IgM ACPA isotypes
PR patients had a lower frequency of IgA and IgM
ACPA isotypes, which was significant in the case of IgA
and IgM against fibrin p18 and IgA against vimentin p55
(Table 2). Mean levels of fibrin p18 IgA and IgM iso-
types, enolase CEP1 IgM, and p55 vimentin IgA were
lower in PR (Fig. 1e, f, g, h, i, and j). The mean number
of IgA (0.37 ± 0.7 vs. 0.96 ± 0.93; p < 0.001) and IgM
(0.22 ± 0.46 vs. 0.44 ± 0.6; p = 0.04) ACPA isotypes was
lower in PR than in RA patients.
Discussion
We characterized the ACPA immune response in pa-
tients with PR or established RA and found differences
in the response, with a more restricted repertoire in PR
patients. Most PR patients tested positive for the com-
mercial CCP2 test, and revealed an ACPA repertoire
closer to that seen in the preclinical phase of RA [9] or
in unaffected relatives of RA patients than in patients
with RA [12, 19, 20]. In PR patients, we found fewer
ACPA fine specificities, with a significantly lower fre-
quency of antibodies against the citrullinated peptide
from vimentin and less isotype usage.
To our knowledge, this is the first study to analyze the
ACPA repertoire in patients with PR. Analysis of the de-
velopment of the ACPA response in the preclinical
phases of RA showed that ACPA initiates in a restricted
manner and expands over time until clinical synovitis is
present, with no particular citrullinated peptide predom-
inating in the early phases [9]. It is reported that, in
CCP-2-positive patients with arthralgia, the ACPA pro-
file did not differ between patients who evolved or not
to overt arthritis, but patients recognizing two or more
additional citrullinated peptides more frequently devel-
oped arthritis [21] and patients with undifferentiated
arthritis who evolved to RA showed greater recognition
of citrullinated peptides than those who did not [10].
Our results are in agreement with these findings, since
the number of additional citrullinated peptides recog-
nized by ACPA in PR patients was significantly lower
than that observed in RA patients.
The low frequency of ACPA against the citrullinated
peptide from p55 vimentin found in PR (24.1% vs. 59.3%
in RA) is of interest. There are conflicting results on the
diagnostic accuracy and prognostic significance of ACPA
vimentin antibodies compared with other ACPA fine spec-
ificities in RA, probably due to the heterogeneity of the
studies or methodological issues [22, 23]. Their presence
in unaffected relatives of RA patients has been described
as virtually absent in one study [12] whereas a prevalence
of 20% was reported in another study [19].
As in RA [24], the ACPA IgG isotype predominates in
PR, but our results show less ACPA isotype usage in pa-
tients with PR, with significantly less use of IgA and IgM
against citrullinated fibrin peptide and IgA against citrulli-
nated vimentin peptides. Lower frequencies of all ACPA
Table 2 ACPA fine specificities (IgG, IgM, and IgA isotypes) for palindromic rheumatism (PR) and rheumatoid arthritis (RA) groups
IgG IgM IgA Any isotype [+]
PR (n = 54) RA (n = 54) p PR (n = 54) RA (n = 54) P PR (n = 54) RA (n = 54) P PR (n = 54) RA (n = 54) p
p18 α-fibrin,
n (%)
19 (35.2) 26 (48.1) 0.17 7 (13) 21 (38.9) 0.02 10 (18.5) 27 (50) <0.001 28(51.9%) 37(68.5%) 0.077
p55 vimentin,
n (%)
13 (24.1) 32 (59.3) <0.001 5 (9.3) 5 (9.3) 1 9 (16.7) 21(38.9) 0.01 22(40.7%) 40 (74.1%) <0.001
CEP-1 Enolase,
n (%)
16 (29.6) 20 (37.0) 0.37 1 (1.8%) 0 (0) (0.3) 1 (1.8) 3(5.6) 0.3 17(31.5%) 22(40.7%) 0.317
p48 vimentin,
n (%)
1(1.9) 8 (14.8) 0.03 – – – – – – – – –
Significant p values are shown in bold
Table 3 Total number of IgG ACPA specificities in PR and RA
PR RA p
0 23 (42.6%) 12 (22.2%) 0.024
1 17 (31.5%) 17 (31.5%) 1
2 10 (18.5%) 15 (27.8%) 0.25
3 4 (7.4%) 10 (18.5%) 0.08
≥2 14 (25.9%) 25 (46.3%) 0.028
ACPA anti-citrullinated peptide/protein antibodies, PR palindromic rheumatism,
RA rheumatoid arthritis
Significant p values are shown in bold
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Fig. 1 Box plots showing the levels of ACPA fine specificities and isotypes in PR. Box plots shows reactivity profiles as optical density values of anti-cyclic
citrullinated peptide (ACPA) for IgG (a, b, c, d), IgM (e, f, g), and IgA (h, i, j) isotypes. The p18 α-fibrin, p55 vimentin, and CEP-1 enolase fine specificities were
analyzed for IgG, IgM, and IgA isotypes and p48 vimentin for only IgG. ACPA reactivity profiles were compared in 54 patients with palindromic rheumatism
(PR) and 54 patients with rheumatoid arthritis (RA). Mann Whitney p values for between-group differences were calculated. Caution should be taken with
these results because OD values are related to the quantity of antibody present in a nonlinear fashion. When only patients positive (above cut-off levels)
for the respective ACPA isotypes were analyzed, the p values for IgG p18 α-fibrin, p48 vimentin, p55 vimentin, and CEP-1 Enolase were 0.963, 0.667, 0.445,
and 0.02, respectively. The p values for IgM p18 α-fibrin, p55 vimentin, and CEP-1 enolase were 0.126, 0.690, and not calculable (no patients [+] in the RA
group), respectively. The p values for IgA for p18 α-fibrin, p55 vimentin, and CEP-1 enolase were 0.230, 0.929, and 0.500, respectively. Box plots show the
median, percentile 25, percentile 75, minimum, and maximum. Dots represent the value of the observation of one patient. Broken lines indicate the
cut-off values
Fig. 2 Association between the number of citrullinated epitopes recognized and CCP2 levels in palindromic rheumatism (PR) and rheumatoid arthritis
(RA). Box plots show reactivity levels of CCP2 antibody according to the number of citrullinated epitopes recognized by ACPA in PR and RA patients.
Spearman’s correlation coefficient (Rho) tested the strength of this relationship. Values of Rho between 0.4 and 0.6 suggest a moderate correlation.
CCP2 reactivity levels significantly correlate with the number of citrullinated epitopes recognized by ACPA in RA, but to a lesser extent in PR. Box plots
show the median, percentile 25, percentile 75, minimum,and maximum. Dots represent the value of the observation of one patient. Broken lines
indicate the cut-off value. CI confidence interval
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(CCP) isotypes have been observed in patients with undif-
ferentiated arthritis who do not evolve to RA compared
with RA patients [25]. The absence of IgM against peptide
p55 derived from vimentin in most patients with RA and
PR (9.3% in both diseases) in our study is intriguing, since
high recruitment of new B cells might be expected in RA.
However, a similarly low percentage of IgM against the
citrullinated peptide p55 derived from vimentin (7%) has
been found in patients with RA [26].
This lower frequency of isotype usage and fine citrulli-
nated specificities in PR was observed even when the
level of CCP2 did not differ significantly between PR
and RA. We and others have observed that levels of
anti-CCP in PR were similar to those seen in RA [2, 3].
An association between anti-CCP2 levels and the num-
ber of citrullinated peptides recognized has been de-
scribed in RA using an ELISA test [27] or microarray
techniques [27–29], and was observed in RA patients in
the present study; however, we found that this associ-
ation was observed to a lesser extent in PR, although the
low number of recognized epitopes in PR patients limits
data interpretation. Previous studies in patients with
ACPA-positive arthralgia showed a higher risk of RA
progression in patients with high levels of anti-CCP [30],
but in the study of Verpoort et al. [26], although a trend
toward high levels of anti-CCP was observed in patients
with CCP-positive RA compared to CCP-positive undiffer-
entiated arthritis for all isotypes, no significant differences
were observed when negative samples were excluded. The
authors concluded that the level of the different isotypes
did not differ between RA and undifferentiated arthritis,
but the number of antibody-positive patients was higher
in RA than in undifferentiated arthritis. Similar results
were observed in our study.
One limitation of this study is the selection bias to-
wards a more stable population of longstanding PR pa-
tients who are less prone to evolve to RA; thus, the
findings cannot be extrapolated to PR patients with a
short disease duration. The strengths of the study in-
clude the strict selection criteria for PR, excluding other
causes of arthritis and the presence of persistent arthritis
in these patients, and an RA patient population con-
trolled for disease duration and ACPA positivity by the
CCP2 test. Likewise, the high accuracy of home-made
ELISA tests based on citrullinated synthetic peptides in
the diagnosis of RA has been shown in previous studies.
Conclusions
We observed a more restricted pattern of ACPA recogni-
tion in patients with longstanding PR, with fewer fine
specificities (especially in the case of the peptide of citrul-
linated vimentin) and lower isotype usage than in RA pa-
tients, an ACPA repertoire most frequently reported in
the preclinical phase of RA or unaffected relatives of RA
patients. It may be speculated that some patients with PR
who do not evolve to RA may have impaired maturation
of the B-cell response against citrullinated peptides that
may stop the development of chronic arthritis. Prospective
studies in the early phases of PR are warranted.
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